01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024.   Highlights ·    Revenue up 11.9% to £62.7 million (2023: £56.0 million) ·    EBITDA margin of c.26% (2023: 23.3%) ·    Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…

Continue reading

#VELA Vela Technologies PLC – Quarterly Investment Update January 27, 2025 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, today announces an investment update for the quarter ended 31 December 2024. Key numbers as at 31 December 2024 ·        The value of Vela’s total assets (including cash) decreased by £385,000 during the quarter to £2,670,000 from £3,055,000 (quarter to 30 September 2024 – an increase of £251,000). ·        The fair value of the investment portfolio (excluding cash)…

Continue reading

#VELA investee #WCAP WeCap PLC – WeShop SEC Submission December 27, 2024 – Posted in: Vela Technologies Plc (VELA)

WeCap plc is pleased to provide an update on progress of its primary portfolio company, WeShop Holdings Limited (“WeShop”).  WeShop has announced that it has confidentially submitted a draft “Registration Statement” on Form “F-1” to the Securities and Exchange Commission (the “SEC”) relating to the proposed direct listing of its ordinary shares. The direct listing is expected to take place after the SEC completes its review process, subject to market and other conditions. Highlights WeShop has confidentially filed…

Continue reading

#POLB Poolbeg Pharma PLC – POLB 001 Patent Granted in United States November 20, 2024 – Posted in: Poolbeg Pharma (POLB)

20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I patent application. The claims cover POLB 001, and other p38 MAP kinase inhibitors, for the treatment of patients at risk of severe influenza after an…

Continue reading

#VELA Vela Technologies PLC – Interim Results December 22, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies plc (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, is pleased to announce its interim results for the six months ended 30 September 2023. Overview The last six months have continued to be challenging for capital markets with political unrest continuing both at home and abroad, the continuing war in Ukraine and rising inflation and interest rates continue to be factors impacting the small-cap marketplace in…

Continue reading

Vela Technologies Plc #VELA – Quarterly Investment Update June 6, 2023 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, today announces an update for the quarter ended 31 March 2023. Executive Director, James Normand, commented: “The disappointing result for the quarter, reversing the positive result of the previous quarter, reflects the poor state of the quoted markets generally and the market’s continuing abstention from the small cap sector in particular. Vela remains of the view that many of…

Continue reading

#VELA Vela Technologies PLC – Interim Results December 15, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

Overview The last six months have been extremely challenging for capital markets with political unrest both at home and abroad, the continuing war in Ukraine and rising inflation and interest rates. These factors have impacted the small-cap marketplace in the UK; and Vela and its investment portfolio have not been immune to such pressures. Against this backdrop investors have taken a cautious approach with the resultant withdrawal of capital from the markets during the period…

Continue reading

#VELA Vela Technologies – Strategic Update September 2, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

The Board of Vela Technologies plc (AIM: VELA) today provides the following update with regard to the future investment strategy and direction of the Company.   Following the appointment to the board of Antony Laiker, a significant shareholder in Vela, it has been agreed by the Board that, while not diverting from the Company’s underlying investing policy, Vela will consider other corporate transactions whereby Vela’s assets might be utilised to effect one or more larger…

Continue reading